September 19, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: CuraTeQ Biologics Announces Successful Completion of Phase 3 Clinical Study for Denosumab Biosimilar.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company, is pleased to announce the successful completion of a pivotal clinical study evaluating its denosumab biosimilar against Prolia (denosumab) in a cohort of 446 women with postmenopausal osteoporosis. Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints, demonstrating no clinically meaningful differences between the biosimilar and the reference product.

Dr. Arpit Prajapati, Head of Clinical Sciences at CuraTeQ said, "The clinical trial was designed to evaluate the efficacy of the denosumab biosimilar in enhancing bone mineral density (BMD) and mitigating fracture risk in postmenopausal women, a population that is particularly susceptible to osteoporosis. The primary endpoint, defined as the percentage change in Lumbar Spine Bone Mineral Density (LS-BMD) at Week 52, successfully met the pre-defined equivalence margin of (-1.45, +1.45). Additionally, the co-primary endpoint assessing the area under the effect curve (AUEC) of serum C-terminal telopeptide (sCTX) from Week 0 to Week 26 was found to be within the acceptable range of (0.80, 1.25), satisfying regulatory criteria for both the US FDA and the European Medicines Agency (EMA). These findings suggest that CuraTeQ's denosumab biosimilar exhibits comparable efficacy to Prolia, highlighting its potential as a viable alternative for patients in need of osteoporosis treatment"

Dr. Disha Dadke, Head of R&D and Regulatory Sciences at CuraTeQ commented, "CuraTeQ plans to submit regulatory filings for the denosumab biosimilar in the EU, US and other key regulated markets from January 2026. The company's regulatory team has consulted with the FDA and is actively engaging with other regulatory authorities to ensure a smooth filing and an efficient review process."

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.09.19 10:11:57 +05'30'

B. Adi Reddy
Company Secretary